Drug costs for some U.S. seniors to rise by hundreds of dollars

Medicare Part D's catastrophic coverage threshold will go up by $1,250 next year.
OCT 11, 2019
Senior citizens with high prescription drug costs are facing hundreds of dollars in additional expenses next year, according to a new analysis of Medicare's drug program by a nonprofit research group. Medicare's drug benefit, known as Part D, is complicated. Patients in the program have a deductible where they must pay 100% of the cost: $435 in 2020, according to the analysis by the Kaiser Family Foundation. After that, they pay a quarter of the costs until they reach the threshold for catastrophic coverage, when richer benefits kick in. Next year, the catastrophic coverage threshold will go up by $1,250 — meaning people on brand-name drugs will pay about $400 more a year out-of-pocket, according to the analysis. People taking generics will pay even more. High drug costs are a source of discontent among voters. Vying for 2020 voters, the Trump administration has boasted about its efforts to get pharmaceutical companies to lower list prices for medications, while ire at drugmakers and insurers has animated Democratic calls for a broader health care overhaul. Next year's rising costs stem from an expiring part of the Affordable Care Act, which temporarily tamped down increases in the catastrophic coverage threshold. Medicare Part D covers about 44 million Americans on the federal health program for the elderly and disabled. Administered by private insurers, the program distributes the cost of medications among enrollees, health plans, drugmakers and the government. Low-income people in the program get subsidies to help with costs. In 2017, 4.9 million people had drug spending and incomes high enough that they either entered the coverage gap or went all the way through it, according to the Kaiser Family Foundation. [Recommended video: How to help clients make it through retirement] Above the catastrophic coverage level, seniors are on the hook for 5% of medication costs, with no upper limit. Various legislative proposals would cap total out-of-pocket costs for the Medicare drug benefit. A bill supported by Democratic House Speaker Nancy Pelosi would limit seniors' exposure to $2,000, while a proposal advanced by the Republican-controlled Senate Finance Committee would set the limit at $3,200. The Trump administration has also proposed insulating seniors from cost-sharing after they reach the catastrophic threshold. Whether Congress and the administration can agree on a prescription drug bill before the 2020 election remains an open question. If they don't, some seniors may realize they're paying more for their medicine, just as their preparing to go to the polls.

Latest News

Fintech bytes: Envestnet reaffirms $1B RIA commitment with Tamarac tech investment
Fintech bytes: Envestnet reaffirms $1B RIA commitment with Tamarac tech investment

Also, Orion has added BlackRock, Fidelity, and Vanguard to its custom portfolios suite, and RedBlack has set up a new headquarters after crossing a trillion-dollar milestone.

RIA moves: Maridea acquires multigenerational practice in Pennsylvania debut
RIA moves: Maridea acquires multigenerational practice in Pennsylvania debut

Also, New York-based Legacy Edge Advisors names its first-ever CEO, while Novare Capital Management hires a Vanguard veteran with a multigenerational planning focus.

Private equity eyes 401(k) plans, but fees remain a hurdle
Private equity eyes 401(k) plans, but fees remain a hurdle

Asset managers are racing to bring private market products to retirement plans, but cost and liquidity concerns linger.

IRS floats proposal ending tax breaks for schools that weigh race
IRS floats proposal ending tax breaks for schools that weigh race

Treasury's latest tax-exemption crackdown on private schools lands in the wake of a separate push to restrict refundable credits for some immigrant filers.

Trust over tech:  The hidden signal of stock success in the AI era
Trust over tech: The hidden signal of stock success in the AI era

Workforce trust measures predicted which companies came out ahead during COVID-19. The same dynamic may now be playing out across the AI transition — and the data suggests the spread could be just as wide.

SPONSORED Direct indexing webinar targets tax-loss harvesting amid market swings

Northern Trust’s Ken Lassner shows advisors how to convert volatility into after-tax portfolio gains

SPONSORED Who builds the income when the pension disappears?

Dan Biagini of American Equity says the steady decline of pensions, longer lifespans and a reset in interest rates are rewriting how advisors build retirement income